Article
GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2
25 Jul 2025
Abstract excerpt
BACKGROUND: Due to the lack of effective targeted therapies and the high likelihood of acquired resistance, triple-negative breast cancer (TNBC) remains one of the deadliest cancers affecting women globally. Investigating the mechanism underlying TNBC's resistance to platinum-based chemotherapy and identifying new therapeutic targets are urgent priorities. METHODS: The expression level of GPX3, cisplatin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
